Background: Previous data showed that non-invasive ventilation (NIV) applied for 3 min before tracheal intubation ensured better oxygenation compared with using a non-rebreather bag-valve-mask. We aimed to determine whether preoxygenation using NIV is effective in reducing the incidence of organ dysfunction in hypoxaemic, critically ill patients in intensive care. Methods: A multicentre, randomised, open-label trial evaluating 100% FiO 2 administered with NIV (99 patients) vs with face mask (102 patients) for 3 min before tracheal intubation. The primary endpoint was the maximal value of Sequential Organ Failure Assessment score within 7 days after intubation. Results: The median (inter-quartile range) values of the maximal value of the Sequential Organ Failure Assessment score within 7 days post-intubation were not significantly different between the two randomised groups: nine (6e12) in the NIV group vs 10 (6e12) in the face mask group (P¼0.65). In patients treated by NIV prior to the randomisation, there was a significant increase in the occurrence in adverse events in patients randomised to face mask [odds ratio¼5.23 (1.61;16.99), P¼0.0059].
Conclusions:
This study failed to demonstrate any benefits of using NIV as a preoxygenation method to reduce organ dysfunction compared with usual preoxygenation in hypoxaemic, critically ill patients requiring tracheal intubation for invasive ventilation. NIV should not be discontinued for preoxygenation in the cases of patients treated by NIV before the decision to intubate. Clinical trial registration: NCT00472160.
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Editor's key points
Preoxygenation of the lungs using non-invasive ventilation (NIV) has been shown to reduce hypoxaemia compared to using a face mask before tracheal intubation. The effect of NIV on outcomes in the critically ill is not known. In this randomised trial, hypoxaemia occurred during intubation in both groups but the incidence was higher in patients whose lungs were preoxygenated using a face mask. This was more marked in patients who had been receiving NIV treatment previously. There was no effect on the development of organ failure or other clinical outcomes, but the study may have been underpowered to detect some differences.
Airway management in hypoxaemic critically ill patients requiring tracheal intubation and invasive ventilation is still a matter of concern. Difficult tracheal intubation has been observed in at least 10% of these patients and is associated with profound oxyhaemoglobin desaturation (SpO 2 <80%) in 25% of cases. 1 Preoxygenation is important; the ultimate goal is to avoid or at least reduce the length and severity of hypoxaemia during laryngoscopy and intubation because of its potential deleterious consequences. The rate of oxyhaemoglobin desaturation mainly depends on the amount of stored oxygen at the onset of apnoea. We have previously evaluated non-invasive ventilation (NIV) as a novel approach to preoxygenation. 2 In acute respiratory failure, NIV improves oxygenation by delivering high oxygen concentration, by unloading respiratory muscle, by recruiting alveoli, and by increasing lung volumes. NIV applied for 3 min before intubation ensured better SpO 2 and PaO 2 values during intubation compared with the usual preoxygenation methodea nonrebreathing bag-valve-mask. 2 However, it is uncertain whether this approach improves clinical outcomes. To date, only one study has examined the benefits of NIV as one of a 10-point intubation management protocol. 3 The authors showed that implementation of such management reduced both severe hypoxaemia and collapse during intubation and within the first hour following the intubation of critically ill patients. Our aim was to ascertain whether NIV is a more effective preoxygenation method for the reduction of organ dysfunction than usual preoxygenation in hypoxaemic, critically ill patients requiring tracheal intubation for invasive ventilation in the intensive care unit (ICU).
Methods
The study was a multicentre, randomised, open-label trial evaluating 100% FiO 2 administered with NIV vs with face mask during 3 min preceding intubation. The study was undertaken according to the Declaration of Helsinki and in keeping with French regulations. The protocol was approved by the national ethical review board (CPP:2006/69). Data were gathered using electronic case report forms by the Clinical Research Unit Lariboisi ere St-Louis, University Paris Diderot which independently undertook all statistical analyses.
Participants
Patients were enrolled at six sites. All patients more than 18 yr old with hypoxaemic acute respiratory failure requiring intubation were eligible for the study. Main exclusion criteria were intubation for encephalopathy or coma, decompensation of chronic respiratory failure, cardiopulmonary resuscitation, and pregnancy.
Randomisation
Patients were assigned via an interactive voice response system at the central randomisation centre, in a 1:1 ratio. Randomisation was stratified according to centre and condition of ventilation at the time of randomisation (oxygen supplementation alone or non-invasive respiratory support). We used the standard operating procedure of the clinical research department to avoid any knowledge of the randomisation list by the participants of the trial.
Data collection
The following data were collected: patient's characteristics; reason for admission; preadmission functional status was assessed using the Knaus scale (A, prior good health, no functional limitation; B, mild to moderate limitation of activity because of a chronic disease; C, serious but not incapacitating restriction of activity; and D, severe restriction of activity, including persons bedridden or institutionalized). 4 The general ICU-specific score (Simplified Acute Physiology Score II) was calculated on Day 1. ; succinylcholine, 1 mg kg
À1
; laryngoscopy with a Macintosh size 3 or 4 blade, and cricoid pressure to secure the airway). After oral intubation, the patient was mechanically ventilated, with a tidal volume of 6e8 ml kg À1 , a respiratory rate of 20 bpm, a PEEP of 5 cm H 2 O, and an FiO2 of 100%. Pulse oximetry (SpO 2 ) was continuously monitored throughout the procedure. Arterial blood gases were sampled before preoxygenation and after intubation (within 30e60 min). The intubation conditions were reported using the intubation difficulty scale. 7 
Endpoints
The primary endpoint of the trial was the maximal value of SOFA score within the first 7 days post-intubation. The secondary endpoints were the following: 1. preoxygenation failure, i.e. requirement for an early stop of preoxygenation and immediate intubation because of absence of improvement or deterioration in SpO 2 ; 2. adverse event during preoxygenation or intubation defined as occurrence of arrhythmia with haemodynamic failure, and/or occurrence of regurgitation (presence of gastric content seen during laryngoscopy), severe O 2 desaturation (SpO 2 <80%), de novo myocardial ischemia (myocardial repolarization and/or elevated serum troponin sampled between 4 and 8 hr after intubation); 3. number of organ failures in the ICU within the first 7 days post-intubation; 4. duration of stay in the ICU calculated as the number of days alive out of ICU within 28 days; 5. duration of ventilation calculated as the number of days alive free of ventilation (invasive or non-invasive) within 28 days; and 6. percentage of death in the ICU within 28 days.
Statistical analysis
A sample size of 100 patients per group was fixed on the basis of a standard deviation for SOFA score around 5 (calculated from data by Moreno and colleagues 8 ) , and the requirement of an 80% power to detect a difference at least equal to two between the two types of preoxygenation by analysis of variance (ANOVA) at a 5% two-sided alpha value. All analyses included the intention-to-treat population (all patients randomly assigned to treatment groups, analysed as randomised). Decision for intubation can occur in patients receiving or not an NIV; this is the reason why the present study was stratified according to the type of ventilation before randomisation. All quantitative variables were analysed using analysis of covariance (ANCOVA). Group of randomisation, centres and strata (i.e. the type of ventilation before randomisation) were included in the model as effects. The baseline value of SOFA score was included as covariate. When the quantitative variables were not Gaussian non-parametric, ANCOVA was used. Binary variables were analysed using multivariate logistic regression. The number of organ failures (ordinal variables with a limited number of categories) was studied using multivariate polychotomous regression. Group of randomisation, centres, and strata were included in the multivariate regression models. Frequencies of patients with at least one adverse event were compared by the Chi-square test. Frequency of adverse events were compared using generalized estimating equations since several adverse events can occur in the same patient. All tests were two-sided with a 5% significance level. All analyses were made using SAS Version 9.2 (from SAS Institute, Cary, North Carolina, USA).
Results
Between July, 2007 and January, 2010, 201 patients were randomly assigned to receive preoxygenation by NIV (99 patients) or face mask (102 patients) before intubation. We excluded six patients (Fig 1) . Baseline characteristics were very similar between the two randomisation groups at the admission (Table 1) , before preoxygenation (Table 2 ), during and after intubation (Table 3) . Among patients randomised, 91 (45%) were already oxygenated via NIV ( Table 2 ). Preoxygenation failure, i.e. requirement for an early stop of preoxygenation and immediate intubation, was observed in five patients and only in the face mask group (Table 3) .
Primary criterion: SOFA max
The median (inter-quartile range) values of the maximal value of the SOFA score within the first 7 days post-intubation were not significantly different between the two randomised groups; nine (six to 12) in the NIV group vs 10 (six to 12) in the face mask group (P ¼ 0.65) ( Table 4) . No significant differences between centres or interactions between strata or centre and randomised procedure were found.
Secondary criteria

Number of organ failures
Statistical distribution of number of organ failures in the two groups is shown in Table 4 . These distributions were not significantly different between the two randomised groups (P ¼ 0.34). The effect of baseline value of SOFA was significant (P < 0.001) whereas the effect of strata was at the limit of significance (P ¼ 0.0504). No significant differences between centres or interaction between strata or centre and randomised procedure were found.
Adverse events during preoxygenation or intubation
The percentage of adverse events was 21.4% in the NIV group vs 28.7% in the face mask group, P ¼ 0.24 (Table 3) . Since for this parameter, the interaction between the randomised procedure and strata was significant, we analysed the randomised procedure for each strata. In patients treated by face mask prior to the randomisation, there was no significant difference between the two randomised groups [odds ratio¼0.678 (0.257;1.773), P¼0.43] whereas in patients treated by NIV prior to the randomisation, there was a significant increase in the occurrence of adverse events in patients randomised to face mask [odds ratio¼5.23 (1.61;16.99), P¼0.0059] ( Table 5) . No significant effects of baseline value of SOFA or centres were found.
Duration of ventilation or stay in ICU
The median (inter-quartile range) values of days alive free of ventilation within 28 days post-intubation were not significantly different between the two randomised groups (Table 4) . Similar conclusions were found regarding the number of days alive outside the ICU, four (zero to 17) in the NIV group vs three (zero to 12) in the face mask group (P ¼ 0.14). 
Death
The percentage of death was not significantly different among the two groups; 31.3% in the NIV group vs 37.3% in the face mask group (P ¼ 0.76). The effect of baseline value of SOFA was significant (P < 0.0001). No significant effect of strata centres or interaction between strata or centre and randomised procedures were found.
Discussion
This study failed to demonstrate any benefits of using NIV as a preoxygenation method to reduce organ dysfunction assessed by the maximal value of the SOFA score within 7 days following intubation compared with the usual preoxygenation in hypoxaemic, critically ill patients requiring tracheal intubation for invasive ventilation in the ICU. However, the results emphasized that NIV should not be discontinued for preoxygenation in the cases of patients treated by NIV before the decision to intubate, as there was a significant increase in adverse events when face mask preoxygenation was used in patients previously receiving NIV. We had put forward the hypothesis that NIV may reduce organ dysfunction. Profound oxyhaemoglobin desaturation has been shown to increase morbidity and mortality in a specific population. We have previously shown that NIV is a safe preoxygenation method which is more effective in preventing arterial oxyhaemoglobin desaturation than the usual method of preoxygenation during tracheal intubation in critically ill patients. 2 The present randomised and multicentric study does not confirm this advantage. Indeed, despite the use of NIV for preoxygenation, up to 18.4% (SpO 2 <80%) of the patients experienced arterial oxyhaemoglobin desaturation during intuba- tion. Although the PaO 2 /FiO 2 ratios were similar for the two groups, the median PaO 2 in those receiving preoxygenation by face mask was 12% higher than those given NIV as preoxygenation (median 82 vs 73 mm Hg) ( Table 2) . Although this difference is not statistically different, it may be clinically relevant and might help to explain why no difference was found between the groups in subsequent organ failures. Adverse events during preoxygenation and intubation were not found to be statistically different between the two groups, although there was a trend to reduce preoxygenation failure when NIV was used as compared with the usual method, P ¼ 0.06 (Table 3) . Also, the patients were found to be less hypoxaemic (PaO 2 >9.33 kPa) and less hypercapnic (PaCO 2 5.47 kPa) than the participants of the previous study (PaO 2 <9.33 kPa and PaCO 2 !6.53 kPa). 2 In the control group, SpO 2 <80% during intubation occurred in 27.7% of the patients. This incidence is much lower than those observed in the previous study (46%), but complies with the findings of a French prospective multiple-centre study. 3 This could at least partly explain why preoxygenation with the usual method was not associated with higher arterial oxyhaemoglobin desaturation events than with NIV. Finally, it is not surprising to observe that NIV does not reduce organ dysfunctions, because there was no more oxyhaemoglobin desaturation as compared with using a usual preoxygenation method. The most relevant serious adverse event with a major impact on the primary outcome chosen here would be a hypoxic cardiac arrest, which is obviously a rare situation. Despite the inclusion of about 200 patients, the study might still be underpowered to detect these rare scenarios. The decision to use intubation can occur in patients treated with NIV. This is why the present study was stratified according to the type of ventilation before randomisation. In this group, when NIV was moved to a non-rebreather bag-valvemask for the preoxygenation, there was a significant increase in the occurrence of adverse events (odds ratio ¼ 5.23, Table 5 ).
Recent surveys show that NIV is being increasingly used as first-line ventilatory therapy for acute hypoxaemic respiratory failure. 9 To date, NIV is initiated in up to 20e30% of the patients as a trial ventilatory support instead of invasive ventilation for acute respiratory syndrome. 10, 11 NIV reduces the rate of intubation and subsequent invasive ventilation in a selected population with acute hypoxaemic respiratory failure such as surgical or immunosuppressed patients. 12e14 As a consequence, NIV is gaining in popularity among intensivists. In our study, among randomised patients, 91 (45%) were already oxygenated using NIV before the decision to intubate. Miguel-Montanes and colleagues 15 reported for the first time on the use of high-flow nasal cannula oxygen as an alternative preoxygenation technique. This device can be used to deliver up to 60 litre min À1 oxygen with the ability to reach 100% FiO 2 . In this pivotal before-after study, the authors showed that as a preoxygenation method, high-flow nasal cannula oxygen significantly reduced hypoxaemia during intubation as compared with a non-rebreather bag-valvemask. One of the main advantages of this approach is the possibility to oxygenate (apneic oxygenation) the patient during the whole intubation procedure. However, despite this theoretical advantage, two recent multicentre randomised studies did not confirm the benefit of this approach.
16,17
Conclusions
This multicentre, randomised study failed to demonstrate that NIV is more effective as a preoxygenation method in reducing organ dysfunction than usual preoxygenation in hypoxaemic, critically ill patients requiring tracheal intubation. However, in patients treated by NIV before the decision to intubate, NIV should be pursued for preoxygenation, as it enables the reduction of severe hypoxaemia as compared with using nonrebreather bag-valve-mask.
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